Jazz Pharmaceuticals®

FIRST QUARTER 2021 FINANCIAL RESULTS

MAY 4, 2021

Sara
JZP258 Trial Participant

Life-Changing Medicines. Redefining Possibilities.

Forward-Looking Statements
"Safe Harbor" Statement Under The Private Securities Litigation Reform Act of 1995

This communication contains forward-looking statements regarding Jazz Pharmaceuticals and GW Pharmaceuticals, including, but not limited to, statements related to the anticipated acquisition of GW Pharmaceuticals and the anticipated timing and benefits thereof, including the potential for Jazz Pharmaceuticals to further diversify its revenue, drive revenue growth and deliver substantial and sustainable value; Jazz Pharmaceuticals' expected upcoming value drivers and 2021 goals, including with respect to product and revenue diversification; the near-term blockbuster potential of Epidiolex; Jazz Pharmaceuticals' ability to deleverage and meet its targeted net leverage; potential new product approvals and launches and the anticipated timing thereof; the commercial and growth potential of Jazz Pharmaceuticals' and the combined company's products and product candidates, including Xywav in IH and JZP458 in ALL/LBL, as well as related geographic expansion expectations; expected future oxybate revenue streams, including Jazz Pharmaceuticals' expectations with respect to its receipt of royalties on authorized generic versions of Xyrem; expected initiations of JZP385, JZP150 and Zepzelca clinical trials and the timing thereof; and other statements that are not historical facts.

These forward-looking statements are based on each of the companies' current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with: Jazz Pharmaceuticals' and GW Pharmaceuticals' ability to complete the acquisition on the proposed terms or on the anticipated timeline, or at all, including risks and uncertainties related to securing the sanction of the High Court of Justice of England and Wales and satisfaction of other closing conditions to consummate the acquisition; the occurrence of any event, change or other circumstance that could give rise to the termination of the definitive transaction agreement relating to the proposed acquisition; risks related to diverting the attention of GW Pharmaceuticals and Jazz Pharmaceuticals management from ongoing business operations; failure to realize the expected benefits of the acquisition; significant transaction costs and/or unknown or inestimable liabilities; the risk that GW Pharmaceuticals' business will not be integrated successfully or that such integration may be more difficult, time-consuming or costly than expected; risks related to future opportunities and plans for the combined company, including the uncertainty of expected future regulatory filings, ability of Jazz Pharmaceuticals to obtain regulatory approvals for JZP258, JZP458 and Xywav in IH, product launches, financial performance and results of the combined company following completion of the acquisition; GW Pharmaceuticals' dependence on the successful commercialization of Epidiolex/Epidyolex and the uncertain market potential of Epidiolex; pharmaceutical product development and the uncertainty of clinical success; the regulatory approval process, including the risks that GW Pharmaceuticals may be unable to submit anticipated regulatory filings on the timeframe anticipated, or at all, or that GW Pharmaceuticals may be unable to obtain regulatory approvals of any of its product candidates, including nabiximols and Epidiolex for additional indications, in a timely manner or at all; disruption from the proposed acquisition, making it more difficult to conduct business as usual or maintain relationships with customers, employees or suppliers; the possibility that, if Jazz Pharmaceuticals does not achieve the perceived benefits of the acquisition as rapidly or to the extent anticipated by financial analysts or investors, the market price of Jazz Pharmaceuticals' ordinary shares could decline; potential litigation associated with the possible acquisition; regulatory initiatives and changes in tax laws; market volatility; maintaining or increasing sales of and revenue from Jazz Pharmaceuticals' oxybate products and Jazz Pharmaceuticals' and the combined company's other key marketed products; effectively launching and commercializing Jazz Pharmaceuticals' and the combined company's other products and product candidates; protecting and enhancing the combined company's intellectual property rights; delays or problems in the supply or manufacture of the combined company's products and product candidates; complying with applicable U.S. and non-U.S. regulatory requirements; government investigations, legal proceedings and other actions, including risks related to Jazz Pharmaceuticals' settlement agreements with abbreviated new drug application filers and litigation challenging such settlements; obtaining and maintaining adequate coverage and reimbursement for the company's products; identifying and acquiring, in-licensing or developing additional products or product candidates, financing these transactions and successfully integrating acquired product candidates, products and businesses; Jazz Pharmaceuticals' ability to realize the anticipated benefits of its collaborations and license agreements with third parties; the sufficiency of the Jazz Pharmaceuticals' cash flows and capital resources to fund its debt service obligations, de-lever and meet its stated leverage targets; Jazz Pharmaceuticals' and the combined company's ability to achieve expected future financial performance and results and the uncertainty of future tax and other provisions and estimates; and other risks and uncertainties affecting Jazz Pharmaceuticals and GW Pharmaceuticals, including those described from time to time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals' and GW Pharmaceuticals' Securities and Exchange Commission ("SEC") filings and reports, including Jazz Pharmaceuticals' Annual Report on Form 10-K for the year ended December 31, 2020, GW Pharmaceuticals' Annual Report on Form 10-K for the year ended December 31, 2020, GW Pharmaceuticals' definitive proxy statement filed with the SEC on March 15, 2021, GW Pharmaceuticals' Form 10-Q for the quarter ended March 31, 2021, and future filings and reports by either company. In addition, while Jazz Pharmaceuticals expects the COVID-19 pandemic to continue to adversely affect its business operations and financial results, the extent of the impact on the combined company's ability to generate sales of and revenues from its approved products, execute on new product launches, its clinical development and regulatory efforts, its corporate development objectives and the value of and market for its ordinary shares, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time. Moreover, other risks and uncertainties of which Jazz Pharmaceuticals or GW Pharmaceuticals are not currently aware may also affect each of the companies' forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward looking statements made in this communication are made only as of the date hereof or as of the dates indicated in the forward-looking statements, even if they are subsequently made available by Jazz Pharmaceuticals or GW Pharmaceuticals on their respective websites or otherwise. Neither Jazz Pharmaceuticals nor GW Pharmaceuticals undertakes any obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.

Life-Changing Medicines. Redefining Possibilities.

Non-GAAP Financial Measures

To supplement Jazz Pharmaceuticals' financial results and guidance presented in accordance with U.S. generally accepted accounting principles (GAAP), the company uses certain non-GAAP (also referred to as adjusted or non-GAAP adjusted) financial measures in this presentation. In particular, the company presents non-GAAP adjusted net income (and the related per share measure). Non-GAAP adjusted net income (and the related per share measure) exclude from GAAP reported net income (and the related per share measure) certain items, as detailed in the reconciliation table included in the Appendix to this presentation, and adjust for the income tax effect of non-GAAP adjustments.

The company believes that each of these non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors and analysts. In particular, the company believes that each of these non-GAAP financial measures, when considered together with the company's financial information prepared in accordance with GAAP, can enhance investors' and analysts' ability to meaningfully compare the company's results from period to period and to its forward-looking guidance, and to identify operating trends in the company's business. In addition, these non-GAAP financial measures are regularly used by investors and analysts to model and track the company's financial performance. Jazz Pharmaceuticals' management also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate the company's business and to make operating decisions, and compensation of executives is based in part on certain of these non-GAAP financial measures. Because these non-GAAP financial measures are important internal measurements for Jazz Pharmaceuticals' management, the company also believes that these non-GAAP financial measures are useful to investors and analysts since these measures allow for greater transparency with respect to key financial metrics the company uses in assessing its own operating performance and making operating decisions.

These non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures; should be read in conjunction with the company's consolidated financial statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are not prepared under any comprehensive set of accounting rules or principles. In addition, from time to time in the future there may be other items that the company may exclude for purposes of its non-GAAP financial measures; and the company has ceased, and may in the future cease, to exclude items that it has historically excluded for purposes of its non-GAAP financial measures. For example, commencing in 2020, the company no longer excludes upfront and milestone payments from the company's non-GAAP adjusted net income, its line item components and non-GAAP adjusted EPS. Likewise, the company may determine to modify the nature of its adjustments to arrive at its non-GAAP financial measures. Because of the non-standardized definitions of non-GAAP financial measures, the non-GAAP financial measures as used by Jazz Pharmaceuticals in this presentation and the accompanying tables have limits in their usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies.

Additional Cautionary Language

Certain information in this presentation is based upon management forecasts and reflects prevailing conditions and management's views as of this date, all of which are subject to change. In preparing this presentation, we have relied upon and assumed, without independent verification, the accuracy and completeness of all information available from public sources or which was provided to us by third parties or which was otherwise reviewed by us. The information contained herein is subject to change, completion or amendment and we are not under any obligation to keep you advised of such changes.

INTRODUCTION AND OVERVIEW

BRUCE COZADD
CHAIRMAN AND CHIEF EXECUTIVE OFFICER

Jazz Pharmaceuticals®

Focused Execution Drives Long-Term Value

Significant Execution	Upcoming Value Drivers
GW pharmaceuticals • Announced definitive agreement to acquire GW • On track to close deal in early May • Secured $5.35 billion financing	• Creates a leader in neuroscience with a global commercial and operational footprint well positioned to maximize value • Adds high-growth commercial franchise to neuroscience portfolio with Epidiolex®, with near-term blockbuster potential
xywav™ **EDS and Cataplexy in Narcolepsy**[1] • Continued strong uptake • ~3,900 active patients on Xywav exiting 1Q21 • Obtained broad payer coverage - now at 80% of commercial lives **Idiopathic Hypersomnia**[2] • Positive data at presented at AAN • FDA granted Priority Review • PDUFA target action date set for August 12	**EDS and Cataplexy in Narcolepsy** • Opportunity to add patients previously not prescribed Xyrem® based on sodium concerns • Promotional pull through of broad payer coverage **Idiopathic Hypersomnia**[2] • Expect to launch in 4Q21, pending FDA approval • High overlap with existing narcolepsy call universe • ~37,000 diagnosed IH patients in the U.S. • Likely under-diagnosed; no FDA approved treatment
ZEPZELCA™ • Strong uptake since launch in July 2020 • Net product sales of $90M in 2020 and $54M in 1Q21	• Continued growth in 2L setting across both platinum-sensitive and -resistant patients • Expect to initiate Phase 3 trial in combination with I/O in 1L ES-SCLC in 2021
JZP458 for ALL • Initiated BLA submission under RTOR 4Q20	• Targeting mid-year 2021 launch in the U.S.[2] • High quality therapeutic option with reliable supply

[1] Please see the full prescribing information at www.xywav.com, including BOXED Warning and Medication Guide; [2] Subject to FDA approval

COMMERCIAL PERFORMANCE

DAN SWISHER
PRESIDENT AND CHIEF OPERATING OFFICER

Jazz Pharmaceuticals®

Significant Momentum: Neuroscience Portfolio

OXYBATE

XYREM® xywav™

- Net product sales of $411M, an increase of 1% compared to 1Q20
- Average active patients
  - ~15,700 in 1Q21
  - 4% increase compared to 1Q20
  - 2% increase compared to 4Q20
- Strong Xywav uptake, coupled with utilization of our Xywav patient access programs, resulted in a 3% decrease in revenue bottle volume compared to 1Q20

xywav™

- Net product sales of $75M in 1Q21
- ~3,900 active patients exiting 1Q21
- Strong adoption among existing and new-to-oxybate patients
- Achieved goal of obtaining broad payer coverage; agreements with all three major PBMs, coverage now at 80% of commercial lives
- Preparing for planned 4Q21 launch in IH[1]

SUNOSI®

- Net product sales of $12M, compared to $2M in 1Q20 and $9M in 4Q20
- 10% increase in total U.S. prescriptions in 1Q21 compared to 4Q20
- >90% U.S. commercial lives covered
- European rolling launch progressing well
- Pleased with initial launch of both DTC TV and salesforce realignment

[1] Subject to FDA approval

Executing a Successful Xywav Launch

Launched November 2020 for the treatment of cataplexy or excessive daytime sleepiness in narcolepsy

SODIUM MATTERS

- Xywav is the only approved lower-sodium oxybate
- 92% less sodium than Xyrem (sodium oxybate); reduction of 1,000 to 1,500mg per day
- Unlocking the potential in narcolepsy; educating physicians and patients on the lifelong burden of narcolepsy and high sodium intake
- Opportunity to add patients who previously were not prescribed Xyrem based on sodium concerns
- AHA Sodium recommendations
  - No more than 1,500mg per day for most adults
  - Reduction of 1,000mg per day can improve blood pressure and heart health[1]



[1] AHA website: https://www.heart.org/en/health-topics/high-blood-pressure/changes-you-can-make-to-manage-high-blood-pressure/shaking-the-salt-habit-to-lower-high-blood-pressure - accessed March 3, 2021.

Delivering Meaningful Growth: Oncology Portfolio

ZEPZELCA™

- Strong uptake following July 2020 launch — net product sales of $54M in 1Q21
- Continued patient growth in 2L setting across both platinum-sensitive and -resistant patients
- Included in NCCN® Guidelines
- Positive feedback from physicians and increased awareness through education and promotion

Vyxeos™

- Net product sales of $33M in 1Q21, an increase of 1% compared 1Q20
- Continued geographic expansion underway

DEFITELIO®

- Net product sales of $50M in 1Q21, an increase of 5% compared to 1Q20
- Continued geographic expansion underway

ASPARAGINASE

JZP458[1]

Targeting U.S. launch in mid-2021 — commercial launch preparations well underway

Erwinaze[2]

Erwinaze net product sales of $41M in 1Q21, an increase of 9% compared to 1Q20

[1] Subject to FDA approval; [2] The company's agreement with PBL terminated on December 31, 2020. The company has the right to sell certain Erwinaze inventory post-termination and expects to distribute this Erwinaze inventory during the first half of 2021. Once sales of available inventory are complete, the company will cease recording net sales of Erwinaze.

RESEARCH & DEVELOPMENT

ROBERT IANNONE, M.D., M.S.C.E.
EXECUTIVE VICE PRESIDENT, RESEARCH & DEVELOPMENT AND CHIEF MEDICAL OFFICER

Jazz Pharmaceuticals®

Xywav - Breaking New Ground in Idiopathic Hypersomnia

Priority Review and August 12, 2021 PDUFA Action Date - Target Launch 4Q21[1]



- sNDA accepted by the FDA on April 13, 2021
- Granted Priority Review Designation
- PDUFA target action date of August 12
- Positive Phase 3 trial results presented at the AAN annual meeting demonstrate the potential Xywav has for people living with IH, an often debilitating neurologic sleep disorder[2]

[1] Subject to FDA approval. [2] Jazz is seeking an indication for the treatment of IH based upon the results of this Phase 3 trial

Concept to Approval Capability: Oncology R&D

ZEPZELCA™

- Expect to initiate Phase 3 trial for Zepzelca in combination with immunotherapy in 1L ES-SCLC in 2021
- Jazz and PharmaMar continue to engage with FDA regarding the confirmatory data package

JZP458

- BLA submission initiated in 4Q20 under RTOR
- Targeting U.S. launch in mid-2021[1]
- Enrolment in pivotal Phase 2/3 trial continues; IV cohort initiated
- Anticipate current JZP458 development program will support efforts to seek approval in Europe and Canada
- Working with partner in Japan on regulatory strategy

Vyxeos™

- FDA approved new indication for newly-diagnosed therapy-related AML or AML-MRC in pediatric patients aged one year and older
- Approval supported by safety data from two single-arm trials conducted by the Children's Oncology Group and Cincinnati Children's Hospital
- Demonstrates our commitment to often overlooked patient groups with high unmet need

[1] Subject to FDA approval

FINANCIAL UPDATE

RENÉE GALÁ
EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER

Jazz Pharmaceuticals®

Financial Performance

Strong 1Q21 Performance, Driven Significant Xywav Adoption and Continued Zepzelca Growth

TOTAL REVENUES
Increased 14% Vs 1Q20

23% net product sales from products launched since 2019

Significant adoption of Xywav, driving durable and growing revenues

51% increase in oncology net product sales driven by Zepzelca launch



CASH FROM OPERATIONS

Maintaining strong cash generation as we continue to invest in key launch activities



NON-GAAP ANI[1]

(absolute, and per-share)



Reconciliations of GAAP net income to non-GAAP adjusted net income can be found in the Appendix at the end of this presentation. [1]Commencing in 2020, the company no longer excludes upfront and milestone payments from the company's non-GAAP adjusted net income, its line item components and non-GAAP adjusted EPS. Non-GAAP adjusted net income and non-GAAP adjusted EPS in 1Q20 included the post-tax impact of the $200 million upfront payment made to PharmaMar.

GW Transaction Expected to Deliver Substantial and Sustainable Value

Disciplined Allocation of Capital in Alignment With Our Strategic Priorities

ALIGNED TO CAPITAL ALLOCATION STRATEGY

- Accelerates revenue growth and diversification
- Leading cannabinoid platform significantly expands Jazz's neuroscience pipeline
- Focused on operational excellence to maximize Total Shareholder Return

LEVERAGING FINANCIAL STRENGTH

$2.4B
Cash at end of 1Q21

$Billions
Expected cash flow through 2025

Financing
Secured on favorable terms:
$1.5B Senior Secured Notes
$3.85B term loan

<4% WACD
On track for post acquisition target

DISCIPLINED USE OF CAPITAL

Expect to be EPS accretive in first full year

Commitment to de-lever; targeting <3.5x net leverage by end of 2022



[1] Assumes aggregate consideration of $7.2B including $6.5B in cash, financed by cash on hand and new debt, and $0.7B in Jazz shares.
[2] By the end of 2022

2021 Goals

Aligned to Patient-Centric Strategy and Key Objectives

PATIENT-CENTRIC INNOVATION DRIVES OUR STRATEGY

Innovate to transform the lives of patients

- Expand our pipeline and diversify revenues through acquisitions, collaborations, and internal initiatives
- Build a high value portfolio of assets through disciplined portfolio management and capital allocation

CONTINUED COMMERCIAL EXECUTION EXCELLENCE

Targeted launches

- JZP458 in ALL/LBL mid-year 2021[1]
- Xywav in IH 4Q21[1]

Continue to focus on

- Rapid U.S. adoption and broad access for Xywav
- Sunosi growth globally
- Driving Zepzelca as the treatment of choice for 2L SCLC patients

ROBUST AND PRODUCTIVE PIPELINE

Key Pipeline Milestones

- Initiate Phase 2b trial for JZP385 in ET in mid-2021
- Initiate Phase 2 trial for JZP150 in PTSD in late 2021
- Initiate Phase 3 trial for Zepzelca in combination with I/O in 1L ES-SCLC

2021
5 key launches through 2020 and 2021

2022
~65% of net product sales from products launched since 2019[2]

2023
Majority of all oxybate patients on Xywav

[1] Subject to FDA approval.
[2] Assuming the closing of the GW transaction.

APPENDIX

Jazz Pharmaceuticals®

Delivering Meaningful Shareholder Value

- Patient-Centric Innovation to Drive Our Strategy
- Experienced Leadership Team to Execute on Strategy and Deliver Value
- Strong Financial and Operational Track Record Generating >$2B in Annual Revenue
- High Value Neuroscience and Oncology Products Poised for Continued Growth and Diversification
- Global Commercial Footprint and Operations to Rapidly Advance and Scale Products
- Robust and Productive Development Pipeline Designed for Sustainable Growth
- Strong Balance Sheet and Cash Flow to Enable Strategic and Disciplined Capital Deployment
- Multiple Important Catalysts in 2020–2021 Providing Foundation for Transformative Growth

Oxybate: Durable Revenues and Growth Opportunities

Future oxybate revenue streams and growth driven by Xywav adoption

Oxybate History

XYREM® (sodium oxybate) oral solution CIII

2020 sales over $1.7B
~15,000[1] patients

Over more than 15 years Jazz has:

- Established oxybate therapy as the standard of care in narcolepsy
- Established and operated a robust, FDA approved, REMS and distribution system
- Built trust and strong relationships with narcolepsy physician and patient communities
- Invested to significantly improve oxybate therapy based on patient and physician feedback

The Future of Oxybate

Existing Narcolepsy Market

xywav™

Adopted by ~3,900[3] patients in the first five months of launch

+

New Narcolepsy patients

Opportunity to add patients previously not prescribed Xyrem based on sodium concerns

+

Xywav in IH[2]

Opportunity to reach new patients with idiopathic hypersomnia

+

XYREM®

Jazz will continue to sell Xyrem

Meaningful royalties on Xyrem AGs

GROWTH + DURABILITY

[1]Average active oxybate patients prior to Xywav launch; [2]Subject to FDA approval; [3]Active Xywav patients at March 31, 2021

Significant Product Diversification Expected to be Driven by New Product Growth and GW: 5 Key Product Launches

	PRODUCTS / FUTURE PRODUCTS	LAUNCH STATUS	SOURCE OF OPERATING LEVERAGE
Neuroscience	xywav™	☑	• Utilizes Jazz's established REMS, exclusive pharmacy relationships and has the same physician call point
	Xywav in IH[1]	☐	• High overlap with existing sleep call universe
	SUNOSI®	☑	• Sunosi sales force is established in U.S. and Europe; early in growth
Oncology	ZEPZELCA® (lurbinectedin) for injection 4 mg	☑	• Zepzelca was launched in July 2020 and is scaling rapidly
	JZP458[2]	☐	• JZP458, if approved, will utilize the Jazz infrastructure used to sell Erwinaze
Epilepsy	Epidiolex® (cannabidiol)	☑	• Established infrastructure; launch of all products in both U.S. and Europe still relatively early for all approved indications (TSC approved in U.S. August 2020 and in EU April 2021)

NEW PRODUCTS EXPECTED TO DRIVE GROWTH AND SIGNIFICANTLY DIVERSIFY REVENUES

ADDITION OF GW IMMEDIATELY DIVERSIFIES AND IS EXPECTED TO ACCELERATE JAZZ'S GROWTH PROFILE

[1] sNDA submitted, U.S. launch targeted 4Q21.
[2] U.S. launch targeted mid-2021.

GW Transaction Accelerates Growth and Enhances Diversification

INCREASED SCALE

Total revenue ($B)



Accelerated, Double-Digit Top Line Revenue Growth

IMMEDIATE, ENHANCED DIVERSIFICATION

Revenue contribution



Products Acquired or Launched Since 2019
Expected to Contribute >65% of Net Product Sales in 2022

[1] 2020 pro forma = Jazz actual + GW actual, with no adjustment – subject to deal completion; [2] For illustrative purposes only; [3] Subject to FDA approval

Robust and Productive Pipeline for Sustainable Growth

Targeted Investments Designed to Fuel Growth Through 2025 and Beyond

PRE-CLINICAL

- **Undisclosed targets**
  Neuroscience
- **CombiPlex**
  Exploratory activities
- **JZP341**
  (Long-acting *Erwinia* asparaginase)[2]
  ALL/other hematological malignancies
- **Pan-Raf Inhibitor Program**
  Raf & Ras mutant tumors
- **Undisclosed targets**
  Ras/Raf/MAP kinase pathway[2]
- **Exosome targets (NRAS and 3 others)**[2]
  Hematological malignancies/solid tumors
- **Defibrotide**
  Exploratory activities
- **Undisclosed targets**
  Cannabinoids

PHASE 1

- **JZP324**
  Oxybate extended-release formulation
- **Vyxeos**
  Low Intensity Dosing for higher risk MDS[3]
- **Vyxeos + other approved therapies**
  - R/R AML or HMA Failure MDS[3]
  - First-line, fit AML (Phase 1b)
  - Low Intensity Therapy for first-line, unfit AML (Phase 1b)
- **Additional Cannabinoids**
  Neonatal hypoxic-ischemic encephalopathy
- **Additional Cannabinoids**
  Neuropsychiatry targets

PHASE 2

- **JZP385**[4]
  Essential tremor (Phase 2b)
- **JZP150**[4]
  PTSD
- **Vyxeos**
  - HR-MDS (EMSCO)[5]
  - Newly diagnosed older adults with HR-AML[4,5]
- **Vyxeos + venetoclax**
  de novo or R/R AML[3]
- **Nabiximols**[4]
  PTSD
- **Additional Cannabinoids**
  Schizophrenia
- **Additional Cannabinoids**
  Autism spectrum disorders

PHASE 3

- **Vyxeos**
  - AML or HR-MDS >60 yrs (AML18)[5]
  - AML or HR-MDS >18 yrs (AML19)[5]
  - Newly diagnosed adults with standard- and HR-AML (AMLSG)[5]
  - Newly diagnosed <22 yrs with AML (COG)[5]
- **Nabiximols**
  MS spasticity
- **Nabiximols**[4]
  Spinal cord injury spasticity

REGULATORY

- **JZP258 (Xywav)**
  Idiopathic hypersomnia
- **JZP458**
  (recombinant *Erwinia* asparaginase)
  ALL/LBL (pivotal Phase 2/3)

Neuroscience
Oncology
Cannabinoids[7]

Demonstrated concept to approval capability

xywav™	Launched November 2020
JZP458 in ALL/LBL	Launch targeted mid-year 2021[6]
Xywav in IH	Launch targeted 4Q21[6]

[1] Opt-in opportunity. [2] Partnered collaboration. [3] Jazz & MD Anderson Cancer Center collaboration study. [4] Planned. [5] Cooperative group study.
[6] Subject to FDA approval. [7] Subject to closing GW transaction.

Reconciliation of GAAP Reported to Non-GAAP Adjusted Net Income

In millions, except per share amounts (unaudited)	**1Q21**	**1Q20**
GAAP reported net income (loss)	**$121.8**	**$(157.8)**
Intangible asset amortization	68.2	62.8
Share-based compensation expense	34.5	28.7
Transaction-related expenses[1]	8.3	-
Non-cash interest expense[2]	15.7	12.0
Impairment charge[3]	-	136.1
Income tax effect of above adjustments	(19.6)	(56.0)
Non-GAAP adjusted net income	**$228.9**	**$25.8**
GAAP reported net income (loss) per diluted share	**$2.09**	**$(2.82)**
Non-GAAP adjusted net income per diluted share	$3.92	$0.45
Weighted-average ordinary shares used in diluted per share calculations – GAAP	58.4	56.0
Weighted-average ordinary shares used in diluted per share calculations – Non-GAAP	58.4	56.8

[1]Transaction-related expenses relating to the proposed GW acquisition; [2]Non-cash interest expense associated with debt discount and debt issuance costs; [3]Impairment charge related to the company's decision to stop enrollment in its Phase 3 clinical study of defibrotide for the prevention of veno-occlusive disease.

Glossary of Terms

1L / 2L = 1st Line / 2nd Line
AAN = American Academy of Neurology
AGs = Authorized Generics
AHA = American Heart Association
ALL = Acute Lymphoblastic Leukemia
AML (-MRC)= Acute Myeloid Leukemia (- Myelodysplasia-related Changes)
AMLSG = AML Study Group
ANI = Adjusted Net Income
BLA = Biologics License Application
COG = The Children's Oncology Group
DS = Dravet Syndrome
DTC = Direct to Consumer
EDS = Excessive Daytime Sleepiness
EMSCO = European Myelodysplastic Syndromes Cooperative Group
EPS = Earnings Per Share
ES-SCLC = Extensive Stage Small Cell Lung Cancer
ET = Essential Tremor
FDA = U.S. Food and Drug Administration
GW = GW Pharmaceuticals plc
HMA = Hypomethylating Agent
HR-AML = High-Risk AML
HR-MDS = High-Risk MDS
IH = Idiopathic Hypersomnia
I/O = Immuno-Oncology
IPR&D = In-process Research and Development
IV = Intravenous
LBL = Lymphoblastic Lymphoma
MDS = Myelodysplastic Syndrome
MRC = Myelodysplasia-related Changes
NCCN = National Comprehensive Cancer Network
Oxybate = (Xyrem and Xywav)
PF = Pro-forma
PBL = Porton Biopharma Limited
PBM = Pharmacy Benefit Manager
PDUFA = The Prescription Drug User Fee Act
PharmaMar = Pharma Mar, S.A.
PTSD = Post-Traumatic Stress Disorder
R&D = Research & Development
R/R = Relapsed/Refractory
REMS = Risk Evaluation and Mitigation Strategies
RTOR = Real Time Oncology Review
SCLC = Small Cell Lung Cancer
sNDA = Supplemental New Drug Application
TSC = Tuberous Sclerosis Complex
TV = Television
WACD = Weighted Average Cost of Debt